Home/Pipeline/AMP-303

AMP-303

Androgenetic Alopecia

Phase 1Active

Key Facts

Indication

Androgenetic Alopecia

Phase

Phase 1

Status

Active

Company

Amplifica

About Amplifica

Amplifica is a private, clinical-stage biotech founded in 2019, targeting the multi-billion dollar hair loss market. The company's core technology involves unique signaling molecules to stimulate hair follicles, with its lead candidate, AMP-303, having generated positive first-in-human clinical data. Led by a team with a strong track record in aesthetics and biopharma, including prior successful exits, Amplifica is advancing a pipeline of four next-generation programs and is positioned to capitalize on a significant unmet medical need.

View full company profile

Therapeutic Areas

Androgenic Alopecia Hair Loss

Other Androgenetic Alopecia Drugs

Drug	Company	Phase	Status
FOL-005	Takeda	Phase 2a	Active
TOP-M119	Topadur Pharma	Phase 2	Active
GM-502	Galderma Group	Phase 2	Active
GSK-3β Inhibitor (Topical)	Cosmo Pharmaceuticals	Phase II	Active (via Cassiopea)